Is it still suitable to depend on AstraZeneca for COVID-19 vaccine donations to developing countries? DOI

Abdelrahman M Makram,

Van Phu Tran, Randa Elsheikh

et al.

Current Medical Research and Opinion, Journal Year: 2022, Volume and Issue: 38(12), P. 2127 - 2130

Published: Sept. 27, 2022

The factors associated with hesitancy in receiving the COVID-19 vaccines have been widely examined by several studies worldwide. Although individual attitude plays a significant role vaccine uptake, WHO and public health experts believe that tackling spread of is only achievable guaranteeing equity across globe, especially low-and-middle-income countries, where vaccination process being hindered other besides hesitancy. Among these refusal AstraZeneca because its short shelf life. Therefore, we aimed this letter to propose some solutions may contribute solving specific problem.

Language: Английский

Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study DOI Creative Commons
Sivan Gazit, Yaki Saciuk,

Galit Perez

et al.

BMJ, Journal Year: 2022, Volume and Issue: unknown, P. e071113 - e071113

Published: May 24, 2022

To examine the relative effectiveness of a fourth dose Pfizer-BioNTech mRNA (BNT162b2) vaccine compared with three doses over span 10 weeks. Retrospective, test negative, case-control study, matched analysis and an unmatched multiple tests analysis. Nationally centralised database Maccabi Healthcare Services, Israeli national health fund for 2.5 million people; from January 2022 (seven days after was first given to eligible individuals) 13 March 2022, omicron dominant period in Israel. 97 499 Services members aged 60 years older, who were receive obtained at least one polymerase chain reaction (PCR) during study. Breakthrough SARS-CoV-2 infection, defined as positive PCR performed seven or more inoculation BNT162b2 vaccine; breakthrough infection resulting severe covid-19 disease, hospital admission death related covid-19. 27 876 participants received 69 623 only. Of 106 died follow-up period, 77 had their third only 23 weeks inoculation. In weeks, provided additional protection against both disease vaccine. However, quickly decreased time, peaking week 65.1% (95% confidence interval 63.0% 67.1%) falling 22.0% (4.9% 36.1%) by end period. Unlike maintained high level (>72%) throughout follow-up. relatively rare event, occurring <1% study four A appears have doses. wane sooner than that dose.

Language: Английский

Citations

80
The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far DOI Creative Commons
Vivek P. Chavda, Rajashri Bezbaruah,

Kangkan Deka

et al.

Vaccines, Journal Year: 2022, Volume and Issue: 10(11), P. 1926 - 1926

Published: Nov. 14, 2022

The world has not yet completely overcome the fear of havoc brought by SARS-CoV-2. virus undergone several mutations since its initial appearance in China December 2019. Several variations (i.e., B.1.616.1 (Kappa variant), B.1.617.2 (Delta B.1.617.3, and BA.2.75 (Omicron variant)) have emerged throughout pandemic, altering virus's capacity to spread, risk profile, even symptoms. Humanity faces a serious threat as long keeps adapting changing fundamental function evade immune system. Delta variant two escape alterations, E484Q L452R, well other mutations; most notable these is P681R, which expected boost infectivity, whereas Omicron about 60 with certain deletions insertions. 40-60% more contagious comparison Alpha variant. Additionally, AY.1 lineage, also known "Delta plus" variant, surfaced result mutation was one causes life-threatening second wave coronavirus disease 2019 (COVID-19). Nevertheless, recent variants represent reminder that COVID-19 epidemic far from ending. sparked fervor investigation on why initially appeared propagate so much rapidly than three concerns (VOCs), whether it threatening those ways, how type mutations, induce minor changes proteins, can wreck trouble. This review sheds light pathogenicity, treatments, impact vaccine efficacy

Language: Английский

Citations

77
COVID-19 vaccine strategies must focus on severe disease and global equity DOI
Peter McIntyre, Rakesh Aggarwal, Ilesh Jani

et al.

The Lancet, Journal Year: 2021, Volume and Issue: 399(10322), P. 406 - 410

Published: Dec. 16, 2021

Language: Английский

Citations

78
End COVID-19 in low- and middle-income countries DOI
Ahmed Mushfiq Mobarak, Edward Miguel, Jason Abaluck

et al.

Science, Journal Year: 2022, Volume and Issue: 375(6585), P. 1105 - 1110

Published: March 10, 2022

Language: Английский

Citations

56
Vaccination against SARS-CoV-2 infection among vulnerable and marginalised population groups in Denmark: A nationwide population-based study DOI Creative Commons
Sandra Feodor Nilsson, Thomas Munk Laursen, Merete Osler

et al.

The Lancet Regional Health - Europe, Journal Year: 2022, Volume and Issue: 16, P. 100355 - 100355

Published: March 25, 2022

Social deprivation, psychiatric and medical disorders have been associated with increased risk of infection severe COVID-19-related health problems. We aimed to study the rates SARS-CoV-2 vaccination in these high-risk groups.Using health, vaccination, administrative registers, we performed a population-based cohort including all Danish residents aged at least 15 years, December 27, 2020, October 15, 2021. Population groups were people experiencing: (1) homelessness, (2) imprisonment, (3) substance abuse, (4) mental illness, (5) supported housing, (6) admission, (7) chronic condition. The outcome was vaccine uptake two doses against infection. calculated cumulative adjusted incidence rate ratios (IRRs) relative general population by sex group.The included 4,935,344 individuals, whom 4,277,380 (86·7%) received vaccine. Lower found for socially deprived psychiatrically vulnerable compared population. Lowest below 65 years experiencing homelessness (54·6%, 95% confidence interval (CI) 53·4-55·8, p<0·0001). After adjustment age calendar time, markedly lower (IRR 0·5, CI 0·5-0·6 males 0·4, 0·4-0·5 females) similar results imprisonment. also most IRR abuse 0·7, 0·7-0·7 0·8, 0·8-0·8 females). Individuals new-onset illness and, especially, those housing conditions had highest among studied groups.Especially, groups, but individuals vulnerability need higher priority implementation strategy increase equity immunization uptake.Novo Nordisk Foundation.

Language: Английский

Citations

29
Non-Arteritic Anterior Ischemic Optic Neuropathy Following COVID-19 Vaccination DOI Creative Commons
Wen-Yun Lin, Jin-Jhe Wang, Chien‐Hsiung Lai

et al.

Vaccines, Journal Year: 2022, Volume and Issue: 10(6), P. 931 - 931

Published: June 10, 2022

People are advised to receive a vaccine booster as the Delta and Omicron variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerge, but various adverse ocular reactions after vaccination have been reported. NAION following COVID-19 appears extremely rarely. Here, we report case 61-year-old female with sudden painless blurred vision developing receiving ChAdOx1 nCoV-19 (AstraZeneca) provide an in-depth explanation possible mechanisms regarding hypercoagulable state vaccination. Our adds literature on potential effects vaccination, ophthalmologists recommend that clinicians should increase awareness this complication when evaluating patients visual disturbance recent history

Language: Английский

Citations

11
Multilevel determinants on COVID-19 booster intention among Americans DOI
Feng Hao

Preventive Medicine, Journal Year: 2022, Volume and Issue: 164, P. 107269 - 107269

Published: Sept. 23, 2022

Language: Английский

Citations

11
Modeling and predicting individual variation in COVID-19 vaccine-elicited antibody response in the general population DOI Creative Commons
Naotoshi Nakamura, Yurie Kobashi,

Kwang Su Kim

et al.

PLOS Digital Health, Journal Year: 2024, Volume and Issue: 3(5), P. e0000497 - e0000497

Published: May 3, 2024

As we learned during the COVID-19 pandemic, vaccines are one of most important tools in infectious disease control. To date, an unprecedentedly large volume high-quality data on vaccinations have been accumulated. For preparedness future pandemics beyond COVID-19, these valuable datasets should be analyzed to best shape effective vaccination strategy. We collecting longitudinal from a community-based cohort Fukushima, Japan, that consists 2,407 individuals who underwent serum sampling two or three times after two-dose with either BNT162b2 mRNA-1273. Using individually reconstructed time courses vaccine-elicited antibody response based mathematical modeling, first identified basic demographic and health information contributed main features dynamics, i.e., peak, duration, area under curve. showed dynamics were partially explained by underlying medical conditions, adverse reactions vaccinations, medications, consistent findings previous studies. then applied factors recently proposed computational method optimally fit “antibody score”, which resulted integer-based score can used as basis for identifying higher lower titers information. The easily calculated themselves practitioners. Although sensitivity this is currently not very high, future, more become available, it has potential identify vulnerable populations encourage them get booster vaccinations. Our model extended any kind therefore form policy decisions regarding distribution strengthen immunity pandemics.

Language: Английский

Citations

2
Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up DOI Creative Commons
Niels Adriaenssens, Béatrice Scholtes, Robin Bruyndonckx

et al.

BMJ Open, Journal Year: 2022, Volume and Issue: 12(9), P. e065897 - e065897

Published: Sept. 1, 2022

Objectives To estimate the prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers (PHCPs). Design Prospective cohort study with 12 months follow-up. Setting Primary care in Belgium. Participants Any general practitioner (GP) working Belgium any other PHCP from same GP practice who physically manages (examines, tests, treats) patients were eligible. A convenience sample 3648 eligible PHCPs 2001 practices registered for this (3044 604 to start December 2020 January 2021, respectively). 3390 (92,9%) participated their first testing time point (2820 565, respectively) 2557 (70,1%) last (December 2021). Interventions asked perform a rapid serological test targeting IgM IgG receptor binding domain complete an online questionnaire at each maximum eight points. secondary outcome measures The both after natural infection vaccination. Results Among all participants, 67% women 77% GPs. Median age was 43 years. seroprevalence (before vaccination availability) 15.1% (95% CI 13.5% 16.6%), increased 84.2% 82.9% 85.5%) March 2021 (after reached 93.9% 92.9% 94.9%) (during booster availability fourth (delta variant dominant) COVID-19 wave). not (yet) vaccinated participants monthly estimated be 2.91% 1.80% 4.01%). is higher self-reported infection. Conclusions This confirms that occupational health provided sufficient protection when managing patients. High uptake resulted high Longevity supported by virus circulation. Trial registration number NCT04779424 .

Language: Английский

Citations

7
Social network, political climate, income inequality, and Americans uptake of monovalent COVID-19 booster DOI
Feng Hao, Wanyun Shao

Vaccine, Journal Year: 2023, Volume and Issue: 41(41), P. 6077 - 6082

Published: Aug. 29, 2023

Language: Английский

Citations

4